about
Clinical features of Thai male lupus: an age-matched controlled study.Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality.Human pythiosis, a rare cause of arteritis: case report and literature review.APLAR rheumatoid arthritis treatment recommendations.Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout.Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.Performance of the Existing Classification Criteria for Gout in Thai Patients Presenting With Acute Arthritis.Prevalence and predictors of depression in patients with systemic lupus erythematosus: a cross-sectional study.The Correlation of Muscle Biopsy Scores with the Clinical Variables in Idiopathic Inflammatory Myopathies.A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria.Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases.Performance of the 2015 American College of Rheumatology/European League Against Rheumatism gout classification criteria in Thai patients.Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study.Performance of Ultrasound in the Diagnosis of Gout in a Multicenter Study: Comparison With Monosodium Urate Monohydrate Crystal Analysis as the Gold Standard.Prevalence and predictors of hand involvement in Thai patients with systemic sclerosis.Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard.Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria.Acute bone infarction: a rare complication in thalassemia.Streptococcus agalactiae: an emerging cause of septic arthritis.Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises.Deforming Arthropathy in Thai Patients With Systemic Lupus Erythematosus.Diagnostic Arthrocentesis for Suspicion of Gout Is Safe and Well Tolerated.Pseudoseptic arthritis: an unusual presentation of neuropathic arthropathy.Performance of classification criteria for gout in early and established disease.The reliability, validity and responsiveness of the Thai version of Systemic Lupus Erythematosus Quality of Life (SLEQOL-TH) instrument.Raised chondroitin sulfate epitopes and hyaluronan in serum from rheumatoid arthritis and osteoarthritis patients.A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout.Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study.Validation of a definition for flare in patients with established gout.Associated factors and psychotherapy on sleep disturbances in systemic lupus erythematosus.2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association.Effects of green tea extract on serum uric acid and urate clearance in healthy individuals.Periodontal disease in Thai patients with rheumatoid arthritis.An insight into rheumatology in Thailand.Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: a comparison using control sera obtained from healthy individuals and patients with multiple medical problems.CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.Development of the Asia Pacific Lupus Collaboration cohort
P50
Q33376598-D3BD256E-22D6-4EBD-B5A0-D78CE2040BCFQ34066760-F4492417-37D5-4A1C-A82D-762F5A55A346Q35606382-3093E4C9-EFB1-4ABD-8ADD-093393AB3457Q35762912-31054ED5-DEA6-4B2B-916A-A1710C25095EQ35803646-4B34AFBE-6211-421A-8F0F-85471E2A1C92Q36069077-5B7C0DB9-D881-41D7-85CC-CD1B8159D8FFQ36188027-8BD2A790-27EB-4D72-BA3C-3627562EF25EQ36315477-7FBBDE17-5B23-4F7E-BC16-7E2C94925B8DQ36567033-BEC9334C-1D82-4AA2-8A53-8CA22C1FCB0EQ36919545-1E108AB2-3B65-4FF9-B9BB-DAB2D765348BQ37570702-3055DB4C-6783-4FA7-8C6D-F4CE006E7D87Q38082506-83E25FBB-6881-4E9B-BACF-0B640015418DQ38585387-C84434CB-BC81-428D-9E08-E00F80DBD426Q38872108-7A82855C-9D35-4E9C-B3A0-669CD0FD7992Q38943509-8833460F-F558-42BA-B140-189D38019663Q39283966-28AB6480-33BA-4858-AF55-24FB9C6B8CE8Q39561180-6CE8BCC8-00A2-4674-996C-AEC5E5F4444DQ39889262-6522388E-DAAE-42F3-AE4D-859336D9AF25Q40049550-F6949D9E-A28F-4572-8224-D9FF47AFB0D7Q40108761-327CC1E9-BCD5-4D54-9119-7CC0FCD4C216Q40217056-B4C7524B-8F2F-48D9-9F61-02D143743742Q40492098-DC52189E-1951-4593-BBF8-571CC3EA685CQ41029672-1CF95CD9-5C69-49D0-83B8-F2FD412723EBQ41079935-B1A82579-4215-4F8C-BEAF-933D1B57D6A0Q41240665-E96C0D2E-785B-481B-A351-F509CD670527Q44646610-B1B2B66F-23DD-4CF0-B8A6-27CE23E1A80DQ45743916-D9D983FF-BE4C-4D61-87B0-A14ACAEAA64EQ46821927-927A91A4-636A-4963-AF42-57AEEC41516BQ46869190-0BCF3667-8334-4B77-8946-EC72EE736044Q47226466-6BF83195-88AB-4512-B2C7-E7654107E97BQ47435133-8060E643-891B-4178-84EE-B0F17AC025C2Q47973775-0EFFA5D0-97E1-45C9-AF48-4875D0DBB91CQ48089791-1AD7E193-A544-43F5-B0DD-448010F06604Q49160612-F78FA5CA-2822-416E-90D9-CAA31D9535CFQ50450500-E8C96EEF-7020-45A5-BA49-52EDAC4948F7Q50716485-C22A1737-8370-4016-8370-7269EDB34B56Q51256644-F4A6FB6F-D77B-4CD3-BC8E-4662FFC7FCD8Q53075216-E4A0CF15-CAA7-45B2-BF26-4F34F74DA75DQ54324459-DEADC80D-8DFE-4712-B8C7-F1C21216836DQ58610580-1EB9AE7D-146D-4339-A0DE-4F1E7428DDA4
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Worawit Louthrenoo
@ast
Worawit Louthrenoo
@en
Worawit Louthrenoo
@es
Worawit Louthrenoo
@nl
type
label
Worawit Louthrenoo
@ast
Worawit Louthrenoo
@en
Worawit Louthrenoo
@es
Worawit Louthrenoo
@nl
prefLabel
Worawit Louthrenoo
@ast
Worawit Louthrenoo
@en
Worawit Louthrenoo
@es
Worawit Louthrenoo
@nl
P106
P1153
7004628644
P31
P496
0000-0003-3105-6122